Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Verona Pharma

IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout

Tuesday's Stock Of The Day is testing a buy point after Verona Pharma broke out last week on blowout sales for its COPD treatment.

Investors Business Daily

Verona Pharma Keeps Hitting New Highs

Verona Pharma Keeps Hitting New Highs

Summary Verona Pharma (VRNA) shows strong technical indicators with a 54.89% gain since 11/19, driven by Barchart's Trend Seeker buy signal. The company focuses on developing ensifentrine for respiratory diseases, currently in Phase 3 trials, with multiple inhaler formulations. Barchart's technical indicators highlight 100% buy signals, a 222.12% gain in...

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 Standout Biotech Stocks With 32% to 63% Upside

A strong pipeline of products could potentially transform these companies, but there are risks.

Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High

Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Verona Pharma Q1 Earnings

Recap: Verona Pharma Q1 Earnings

Verona Pharma (NASDAQ:VRNA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Verona Pharma Q1 2022 Earnings Conference Call On May 3, 2022 At 09:00 AM ET

Verona Pharma Q1 2022 Earnings Conference Call On May 3, 2022 At 09:00 AM ET

Verona Pharma (NASDAQ:VRNA) will host a conference call at 09:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Verona Pharma (VRNA) Conference Call Follow this link to access the live webcast.

Verona Pharma: Q4 Earnings Insights

Verona Pharma: Q4 Earnings Insights

Verona Pharma (NASDAQ:VRNA) reported its Q4 earnings results on Thursday, March 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Organisations

Food and Drug Administration

B of A Securities

US Food and Drug Administration

Zoom Video Comms

Arthur J Gallagher

FactSet Research Systems

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

265,957 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play